Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBT Margin (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed EBT Margin for 14 consecutive years, with 478.31% as the latest value for Q1 2026.

  • For Q1 2026, EBT Margin rose 55930.0% year-over-year to 478.31%; the TTM value through Mar 2026 reached 642.35%, down 255243.0%, while the annual FY2025 figure was 765.89%, 273304.0% down from the prior year.
  • EBT Margin hit 478.31% in Q1 2026 for Agios Pharmaceuticals, up from 546.18% in the prior quarter.
  • Across five years, EBT Margin topped out at 11167.28% in Q3 2024 and bottomed at 12073.44% in Q1 2022.
  • Average EBT Margin over 5 years is 1146.23%, with a median of 1134.03% recorded in 2024.
  • Year-over-year, EBT Margin soared 1240156bps in 2024 and then plummeted -1197033bps in 2025.
  • Agios Pharmaceuticals' EBT Margin stood at 2150.44% in 2022, then surged by 37bps to 1350.7% in 2023, then increased by 27bps to 982.28% in 2024, then soared by 44bps to 546.18% in 2025, then grew by 12bps to 478.31% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods came in at 478.31%, 546.18%, and 803.05% for Q1 2026, Q4 2025, and Q3 2025 respectively.